Dianthus Therapeutics, Inc.
DNTH
Rangering i aksjer
#3909
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aksjekurs
$75.21
Sist synkronisert: 2026-10-19
Markedsverdi
$4.21B
Endring (1 dag)
4.33%
Endring (1 år)
108.93%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
P/S-forhold for Dianthus Therapeutics, Inc. (DNTH)
P/S-forhold per October 2026 TTM: 2.20K
Ifølge Dianthus Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 2.20K. Ved slutten av 2023 hadde selskapet et P/S-forhold på 18.97.
P/S-historikk for Dianthus Therapeutics, Inc. fra 2016 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 2.20K | 1,785.51% |
| 2024 | 116.48 | 514.17% |
| 2023 | 18.97 | 413.89% |
| 2022 | 3.69 | -97.76% |
| 2021 | 164.92 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -99.54% |
US
|
|
| 40.55 | -98.15% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.54% |
NL
|
